Acetaminophen is a commonly used analgesic, available without prescription. Several of its metabolites have heretofore been isolated from physiologic fluids and analytically characterized.
In general, the separation methods are complicated, usually requiring extensive sample pretreatment, and do not measure the individual conjugated metabolites. High-resolution anionexchange separation of urinary samples from subjects receiving acetaminophen reveals eight chromatographic peaks, representing seven metabolites and the free drug itself. Metabolites separated include 2-methoxyacetaminophen, its glucuronide and sulfate conjugates, the sulfate conjugate of 2-hydroxyacetaminophen, the glucuronide and sulfate conjugates of acetaminophen, S-(5-acetamido-2-hydroxyphenyl)cysteine, and S-(5-acetamido-2-glucuronosidophenyl)cysteine. Urinary and serum concentrations of the drug and its seven metabolites were determined by high-resolution liquid chromatography as a function of time after two clinically normal men ingested 1950 mg of the drug. Concentrations in urine and serum are compared, and estimated urinary excretion rates are reported for all metabolites except S-(5-acetamido-2-hydroxyphenyl)cysteine.
Serum concentrations of the glucuronide were higher than concentrations of the free drug 2 h after the drug was ingested, indicating that solvent-extraction procedures for serum will yield low estimates of total drug unless hydrolysis precedes the extraction step. men. Concentrations in serum were also determined periodically during a 3-h period after drug ingestion. Several new metabolites of AAP in humans are reported. Metabolites were identified by gas chromatography, mass spectrometry, and the two techniques combined. Details of the identification of one important new metabolite of acetaminophen are presented here; complete details of studies on other new metabolites, including gas-chromatographic and mass-spectrometric data, will be presented in a subsequent paper.
Materials and Methods

Chromatographic System
The chromatographic system used for these studies isgenerally similarto that described previously (12) . A more complete descriptionof the system used here can be found in a laterpublication by Katz et al. (13) . Certain modifications were introduced into the system, which enabled the chromatographic analysis of acetaminophen and related metabolites to be completed in 21 h. Thus, including system regeneration, the total cycle time was 24 h/sample. These modifications included the following: (a) reduction in column length from 150 to 100 cm, (b) increasingthe column temperature from 60 to 70 #{176}C, and (c) decreasing the total amount of eluting buffer from 350 g to 225 g while at the same time sharpening the gradient. The concentration gradient of buffer eluent was formed by using a nine-chamber gradient box (Phoenix Precision Instrument Co., Philadelphia, Pa.) with 25 g of pH 4.4 ammonium acetate-acetic acid buffer per chamber (15 mmol/liter in the first two chambers, 4 mol/literin the second two chambers, and 6 mol/liter in the finalfivechambers). This relativelysteep gradient and higher temperature enabled elution of three highly anionic sulfate conjugates in 21 h, allowing one sample per day to be analyzed. With use of the previous gradient (12) and a 150-cm column at 60 #{176}C, these strongly retained compounds required 42 h to elute. Extensive band-broadening resulted from such long retention on the column, making quantitation difficult. were collected, consuming a light lunch. Total urinary output was collected during each of the following time periods after ingesting the drug: 0-0.5, 0.5-1, 1-2, 2-3, 3-5, 5-7, 7-12, and 12-24 h. Urine samples were filtered through a 0.2-zm (average pore diameter) filter (Nalge, Sybron Corp., Rochester, N. V. 14602) to remove particulatematter and then frozen at -60 #{176}C untilchromatographic analysis.Blood samples were allowed to clotat ambient temperature. The clotwas centrifuged and the serum was ultrafiltered overnight (0 #{176}C) through dialysistubing (Union Carbide Corp., Food Products Division) with an air overpressure of 104 kPa (15 psig).The ultrafiltered serum samples were stored at -60 #{176}C until analyzed by liquidchromatography.
Results
Metabolite Identification
Figure 1 depicts a typical urinary chromatogram obtained for a patient receivingthe analgesicmedication, AAP. The anion-exchange system used to obtain this chromatogram employed a more gentle gradient (12) and did not incorporate the changes mentioned above (Materials and Methods); therefore, the time required for complete development of this illustrativechromatogram was 42 h instead of the 21 h required for the data of our study. We have identified seven metabolites of acetaminophen in urine samples from human subjects receivingthe drug as shown in Figure 1 : and identification studies for it will be discussed with reference to our data for S-(5-acetamido-2-hydroxypheny!)cysteine, partially characterized by Jagenburg and Toczko (2) and completely identified by means of the total synthesis of I by Focelia et a!. (18) . Ultraviolet absorption maxima obtained for I in 0.1 mol/liter HC1 and 0.1 mol/liter NaOH agreed with those reported for the synthetic compound in Table 2 of this reference. Identification data on other metabo!ites, including mass spectral and gas-chromatographic retention data, will be presented elsewhere.
Ultraviolet spectra for compounds I and VI in methanol were virtually identical, with maxima for the former observed at 244 and 299.5 nm and for the latter at 244 and 300.5 nm. Figure 2 illustrates the mass spectrum obtained for a probe-inserted sample of I. Empirical formulas for all ions were confirmed by high-resolution mass spectrometry except for m/e 226 (not observed in the high-resolution spectrum). However, a metastable transition observed in the mass spectrum at m/e 171.7 (m*)4 related the ions m/e 226 and 197 and suggested a loss of methylene imine (CH2=NH).
Metabolite I had very low volatility in the mass spectrometer, requiring high temperature (>200 #{176}C) for a useful spectrum. No masses were observed above those indicated in Figure 2 . The identity of I was confirmed by the mass spectrum of the trimethylsi!yl derivative, as shown in pirical formulas for all ions pictured in Figure 3 were confirmed by high-resolution mass spectrometry (see Table 1 ). The molecular weight of 270 for I [558-288 (four trimethylsilyl groups)] coupled with the presumed identity of the m/e 226 ion in Figure 2 (based on the metastable transition in the low-resolution mass spectrum) suggests partial thermal degradation and loss of CO2 before volatilization of the probe sample. This isa reasonable assumption, considering the probe temperature required to volatilize the compound and its chemical structure.
Conjugated compound
VI was most intractable and difficult to study. A probe sample required even higher temperatures than were required for I, to obtain a mass spectrum of reasonable intensity. The spectrum was identical to that observed for I, except that no m/e 226 ion was observed. High-resolution mass spectrometry verified that the previously identified ions ( Figure 2 ) were present. A mass spectrum of the trimethylsilyl derivative (gas chromatographic inlet)was quite complex and impossible to interpret. derivative, as shown in Figure 4a . (19) . As illustrated in Figure 4b , these were observed and the compound was verified as a glucuronide.
Highest mass observed for the trimethylsilyl-derivatized conjugate was 691 and for the methylated trimethylsilyl derivative 681, neither of which is nearly high enough for a fully derivatized glucuronide of compound I (mol wt, 950; mol wt of comp. VI, 446 + 7 trimethylsilyl groups). However, we did observe masses that we interpreted as verifying the aglycon as I (see Figure 4b) . Unfortunately, the conjugate was resistant to hydrolysis by fi-glucuronidase (72-h treatment at 37 #{176}C), and acid hydrolysis probably would have cleaved the sulfurcontaining side chain we were attempting to identify. Both I and VI showed a positive reaction with ninhydrin, indicating the presence of a free primary amine functional group. From the nearly identical ultraviolet spectra for I and the glucuronide, the mass spectra! data obtained for the methylated and tn- 
The ultraviolet spectral data indicate that the position of aromatic substitution for the cysteine moiety is identical for compounds land VI.
Metabolite Excretion inUrine
The urinary excretion of the previously listed seven metabolites of AAP was followed as a function of time after two clinically normal subjects ingested 23 mg of AAP per kg of body weight ('1950 mg). This was the first time either subject had ingested this drug. Figure 5 graphically larly, peak excretion by Subject 2 occurred at 2.5 h (collection period 1 h, the 2nd to 3rd hour), while it was delayed until 4 h (collection period 2 h, the 3rd to 5th hour) for Subject 1.
An examination of the excretion rates of AAP during the first half-hour sampling period indicated Subject 1 excreted the free drug at a nate of 1.4 mg/h, whereas the rate for Subject 2 averaged 8 mg/h. Similar differences were noted in a comparison of the excretion rates for the glucuronide during this initial however, rechromatography of the fraction containing these compounds was not performed for this study.
It is interesting to note that excretion of the conjugate VI by Subject 1 was threefold higher than was observed for Subject 2 (see Table 2 ). This difference in excretion by the two subjects was also qualitatively observed for I by following the Ce3+ detector response in the two sample series.
Concentrations of AAP and Its
Metabolites in Serum
Blood samples (about 5 ml each) were collected before ingesting AAP and 0.5, 1.0, 2.0, and 3.0 h afterwards. Figure 8 illustrates the concentration changes we observed for AAP and its metabolites in serum samples from Subject 1, by use of the cerate oxidimetric detector.
Generally, this detector was more sensitive than ultraviolet detection for the two cysteinecontaining metabolites by a factor of two to three under our instrumental conditions. It was also more sensitive to the methoxy-substituted metabolites IV and VII; however, it exhibited about the same sensitivity as ultraviolet detection for the other compounds. Figure 8 shows that neither I nor VI was detected (absence of detector response at 2.75 h and 6.75 h) in any of the serum samples from Subject 1, and this was alsotrue for Subject 2. With the cerium oxidimetric detector the lower limit of detectabilityfor the two cysteine-containing metabolites was estimated to be about 50 nanograms per ml of serum. Thus, although we did detect traces of VII in the serum of both subjects (see, for example, 1-and 2-h samples in Figure 8 at about 16 h), neither I nor VI was detected even though the urinary concentration of the latter generally exceeded that of VII (see Table 2 ). It is possible that these two metabolites were bound to macromolecules in the serum. Compounds with molecular weights greter than about 1000 would have been removed from the samples by the ultrafiltration step. by an equivalent difference in the concentration in serum (see also Table 3 ). Concentrations of AAP in serum remained fairly constant over the 3-h period for Subject 1, which does not appear to fit known kinetics of drug elimination at normal dose levels. Concentrations in serum for Subject 2 decreased substantially from the initial highest concentration of 12.4 ig/ml (Table 3) . However, the concentrations in the urine of both subjects seem to more or lessmirror these relativechanges in concentrations in serum (Figure 9 ). The later peaking of metabolite excretion rates in the urine (3 to 5 h period) for Subject 1 compared to that for Subject 2 (2 to 3 h period) seems to correlate with the difference in the rates of elimination for AAP from the sera of the two subjects.
Note that appreciable quantities of conjugate
even exceeding those of the free drug, were present in the serum. Thus, it should be recognized that gas-liq- uid chromatography in which extraction methods are used (20, 21) for determination of AAP in blood are probably measuring only about half of the drug actually present. Sample hydrolysis performed before the extraction step may overcome this problem if additional complications are not introduced by such harsh treatment of the serum.
Discussion
Significance of Compounds /and VI Studies aimed at defining the mechanism by which overdoses of AAP cause hepatic necrosis in rats and mice, and the possible role that glutathione may play in preventing this liver damage, have been performed by Mitchell et al. (25) examined the possibility that glutathione may prevent AAP-induced hepatic necrosis. They found that either glutathione or cysteine completely inhibited the binding of radiolabeled AAP to microsomal protein in vitro. Pretreating mice so as to artificially deplete hepatic glutathione enhanced AAP-induced hepatic necrosis, whereas pretreatment with cysteine, a glutathione precursor, prevented the hepatic necrosis. Finally, administration of AAP resulted in a dose-dependent depletion of hepatic glutathione, and significant covalent bonding of radiolabeled AAP to hepatic macromolecules did not occur until at least 70% of the hepatic glutathion&was depleted. These authors, on the basis of their experimental findings in rats and mice, suggested that a toxic metabolite of AAP isprevented from covalent binding to hepatic macromolecules by preferentialreaction and subsequent detoxication with glutathione.
In man, the importance of glutathione in preventing hepatic damage induced by AAP and other aryl and unsaturated drugs is unknown. Conjugation of drugs with glutathione occurs, but enzyme activities in the liver are reported to be lower in man than in rats and mice (30) . Warner and Lorincz were unable to isolatea glutathione conjugate afteradministering bromobenzene to human subjects (31). Jagenburg and Toczko (2) reported the identificationof S-(1-acetamido-4-hydroxyphenyl)cysteine as a metabolite of both AAP and phenacetin in man; however, there was no evidence cited that indicated glutathione participated in the formation of this metabolite. We crudely estimated excretion of I by the two subjects of this report to be no more than 1% of the ingested dose, while that of conjugate VI was 5% and 1.6%, respectively, for Subjects 1 and 2. Jagenburg et al. (32) reported urinary excretions for I of 0.4, 3.0, and 5.9% by three healthy subjects after oral doses of 1.5 or 2 g of AAP. These same authors reported the isolation of another cysteine-containing metabolite, excreted in amounts ranging from 4.5 to 6.1% of the ingested dose of AAP. The compound which they isolated yielded alanine after desulphurization and subsequent acid hydrolysis. Based on the absence of reaction with ninhydrin (I did react) and also on "the well-known fact that monohalogenated benzenes form N-acetylcysteine derivatives (mercapturic acids) in the animal body," Jagenburg et al. assumed the metabolite to be S-(1-acetamido-4-hydroxyphenyl)-mercapturic acid. It is possible that the metabolite isolated by these authors is the same metabolite that we have identified as S-(5-acetamido-2-glucuronosidophenyl)-cysteine; however, we found that both it and I show a positive reaction with ninhydrin. This compound, shown by us to be a glucuronide by mass spectrometry, was completely resistant to hydrolysis with figlucuronidase after exposure for 72 h at 37 #{176}C at a pH of 5.04. This suggests the possibility of steric hindrance to attachment of the enzyme or an intramolecular complex between the aglycon and the carboxylic acid group of glucuronic acid.
Our evidence for the identification of cysteine as the group attached to the aromatic ring is conclusive only with regard to the attachment of sulfur to the ring (see discussion regarding the mass-spectrometric studies on probe samples of VI). Based on our interpretation of mass spectral data obtained for VI after treatment with diazomethane and bis(trimethylsilyl)trifluoroacetamide (see Figure 4b) and its positive response to ninhydrin, we believe only an alanine moiety is attached to the sulfur (giving cysteine). However, we did not observe a molecular ion (M) [and the characteristic M -15(CH3) ion fortrimethylsilyl derivatives] for the high-molecular-weight conjugate, so that some possibilityfor error still exists. Considering the high molecular weight, the number of polar groups present, and the possibility of an intramolecular bond, it is not surprising that the mass spectral data failed to give a good structural formed via a reaction of cysteine with this same intermediate. These results, coupled with our failure to identify any mercapturic acid metabolite, may argue against reaction of a presumed toxic metabolite of AAP with glutathione as suggested by Mitchell et al. (25) . The protective role suggested by the studies of these authors on rats and mice may actually be played by either cysteine or methionine in human metabolism.
Identifying the precursor of the new conjugated metabolite VI isvitalto further in vivo studies on the nature of the presumed toxic metabolite. The precursor could be either I or V, the glucuronide of AAP. If it is the latter, this probably would rule out epoxide formation (23) as preceding conjugation with the nucleophilic sulfur group. Further studies to clarify this and other questions should add much to our knowledge on metabolism and detoxication of aromatic compounds in the human body, facilitating the ftrmulation of safer and, perhaps, more effective drugs.
It is important to note that recovery of the ingested drug dose averaged 100.6% for the two subjects in this study. This again illustrates the utility of liquidchromatographic techniques in drug studies to enable a wide spectrum of metabolic changes to be observed.
In this way, unexpected metabolic changes induced by a drug can be observed, enabling mechanistic inferences regarding its mode of action to be further tested.
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